No registrations found.
ID
Source
Brief title
Health condition
Dermatomyositis
Sponsors and support
University Medical Centre
Heidelberglaan 100, G02.124
3584CX Utrecht
Netherlands
Intervention
Outcome measures
Primary outcome
In summary, we will determine the initial cutaneous response after UVB provocation of the skin. Specifically we will determine the trafficking of Langerhans cell, leucocytes and lymphocytes and the expression of MMP in skin lesions and compare these with healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption, for which the results have already been obtained.
Secondary outcome
N/A
Background summary
In summary, we will determine the initial cutaneous response after UVB provocation of the skin. Specifically we will determine the trafficking of Langerhans cell, leucocytes and lymphocytes and the expression of MMP in skin lesions and compare these with healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption, for which the results have already been obtained.
Study objective
N/A
Study design
N/A
Intervention
In summary, we will use our phototest protocol for patients with DM;
1. To determine the minimal erythema dose (MED) for UVB, UVA, and visible light.
2. To determine the clinical aspect of the photoprovoked skin lesions.
3. To determine the time interval between the start of phototesting and induction of skin lesions until their resolution.
4. To record any adverse events.
The information thus acquired can be used to advice the patient more specifically on appropriate protection measures that can be taken against environmental UV radiation.
B. Determination of the cellular trafficking in the initial cutaneous inflammation induced by photoprovocation in patients with DM
After determination of the MED for UVB a test area of 5 cm square on the upper back will be exposed to 3 MED UVB.
Skin biopsies (4 mm.) will be taken of the test area at 0, 24, 48 and 72 hours after one single UVB exposure with 3 MED.
These skin biopsies will be compared with those of healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption. The results for these groups have already been obtained.
Department of Dermatology/Allergology,
G02.124,
Heidelberglaan 100
Cornelus J.G. Sanders
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
c.sanders@azu.nl
Department of Dermatology/Allergology,
G02.124,
Heidelberglaan 100
Cornelus J.G. Sanders
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
c.sanders@azu.nl
Inclusion criteria
1. Patients with DM that have been diagnosed according to international accepted guidelines (1-3);
2. The medication that is used by the patients specifically for DM or other related symptoms will be continued during phototesting;
3. The patients should not use corticosteroid creams or sunscreens during phototesting;
4. Patients with DM are invited to participate in this study and are included after signed informed consent is obtained.
Exclusion criteria
Any malignancy for which the patient is treated with cytostatic drugs and/or radiotherapy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL146 |
| NTR-old | NTR181 |
| Other | : N/A |
| ISRCTN | ISRCTN35411849 |